Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

2.6K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
2.6K
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

4.2K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
4.2K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.9K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.9K
Tissue Transplantation01:24

Tissue Transplantation

1.3K
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ruptured distal anterior cerebral artery (A2) aneurysm presenting with simultaneous bilateral intraparenchymal hemorrhage and acute subdural hematoma: A case report and literature review.

Radiology case reports·2026
Same author

HLA-haploidentical hematopoietic stem cells transplantation with regulatory and conventional T-cell adoptive immunotherapy in pediatric patients with very high-risk acute leukemia.

Bone marrow transplantation·2023
Same author

Long-term assessment of clinical outcomes and disease progression in patients with corrected Tetralogy of Fallot.

European review for medical and pharmacological sciences·2021
Same author

The human embryo, subjectivity and legal capacity. Notes in the light of art. 1 of the Italian law on "medically assisted procreation".

La Clinica terapeutica·2019
Same author

The role of 3D imaging in the follow-up of patients with repaired tetralogy of Fallot.

European review for medical and pharmacological sciences·2019
Same author

Safety of ventilation with an argon and oxygen gas mixture.

British journal of anaesthesia·2019
Same journal

Transplant outcomes for patients with severe acquired aplastic anemia over the age of 40 using busulfan, fludarabine, reduced-dose cyclophosphamide, and anti-thymocyte globulin conditioning regimen.

Bone marrow transplantation·2026
Same journal

A holistic prognostic model for leukemia-free survival after allogeneic transplantation in acute leukemia.

Bone marrow transplantation·2026
Same journal

Early software-assisted response predicts survival in a prospective cohort of 258 newly diagnosed cGvHD patients.

Bone marrow transplantation·2026
Same journal

Evaluation of a novel eHealth-facilitated, post HCT-integrated care model on implementation and rehospitalization: results from the Swiss SMILe hybrid-RCT.

Bone marrow transplantation·2026
Same journal

Impact of doublet post-transplant maintenance on outcomes in multiple myeloma: A propensity score matching analysis.

Bone marrow transplantation·2026
Same journal

A multimodal sexual health intervention among hematopoietic stem cell transplant recipients: mediating effects on quality of life and mood.

Bone marrow transplantation·2026
See all related articles

Related Experiment Video

Updated: Apr 11, 2026

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications
08:32

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

Published on: August 9, 2022

4.5K

Next generation HLA-haploidentical HSCT.

M F Martelli1, M D Ianni2, L Ruggeri1

  • 1Division of Hematology and Clinical Immunology, Department of Medicine, University of Perugia, Perugia, Italy.

Bone Marrow Transplantation
|June 4, 2015
PubMed
Summary
This summary is machine-generated.

Adoptive immunotherapy using regulatory T-cells (Tregs) and T lymphocytes in high-risk leukemia patients significantly reduced graft-versus-host disease (GvHD) and leukemia relapse post-transplant.

More Related Videos

Isolation and Transplantation of Hematopoietic Stem Cells HSCs
20:38

Isolation and Transplantation of Hematopoietic Stem Cells HSCs

Published on: February 25, 2007

24.4K
Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

15.0K

Related Experiment Videos

Last Updated: Apr 11, 2026

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications
08:32

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

Published on: August 9, 2022

4.5K
Isolation and Transplantation of Hematopoietic Stem Cells HSCs
20:38

Isolation and Transplantation of Hematopoietic Stem Cells HSCs

Published on: February 25, 2007

24.4K
Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

15.0K

Area of Science:

  • Immunology
  • Hematology
  • Oncology

Background:

  • Allogeneic stem cell transplantation (SCT) relapse remains a significant challenge in high-risk acute leukemia.
  • Current post-transplant relapse rates of approximately 30% are unsatisfactory despite various strategies.

Purpose of the Study:

  • To evaluate the efficacy of adoptive immunotherapy with regulatory T-cells (Tregs) and conventional T lymphocytes in preventing graft-versus-host disease (GvHD) and leukemia relapse.
  • To assess the impact of this approach on engraftment and immune reconstitution in high-risk adult leukemia patients.

Main Methods:

  • Phase 2 study involving 43 high-risk adults undergoing full-haplotype mismatched SCT without post-transplant immunosuppression.
  • Adoptive immunotherapy administered with FoxP3+ T-regulatory cells (2 × 10^6/kg) and conventional T lymphocytes (1 × 10^6/kg).
  • Monitoring of engraftment, GvHD incidence, immune recovery, disease-free survival, and relapse rates.

Main Results:

  • 95% of patients achieved full-donor type engraftment.
  • Only 15% of patients developed grade II acute GvHD, a significant reduction.
  • Disease-free survival probability was 0.56, with a low relapse rate of 0.05 compared to historical controls (0.21).
  • Earlier emergence of specific CD4+ and CD8+ T-cells against opportunistic pathogens observed.

Conclusions:

  • Adoptive immunotherapy with Tregs and T lymphocytes effectively suppresses GvHD without compromising graft-versus-leukemia (GvL) activity.
  • This strategy offers a promising approach to improve outcomes for high-risk acute leukemia patients undergoing SCT.
  • Insights into separating GvL from GvHD were gained through humanized murine models.